Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SHAFTESBURY PLC. We currently have 18 research reports from 2 professional analysts.
|10Feb17 14:15||RNS||Result of AGM|
|10Feb17 07:00||RNS||Finance and trading update|
|09Feb17 12:19||RNS||Holding(s) in Company|
|27Jan17 13:07||RNS||Holding(s) in Company|
|27Jan17 13:06||RNS||Holding(s) in Company|
|12Jan17 10:43||RNS||Holding(s) in Company|
|16Dec16 09:26||RNS||Total Voting Rights|
Frequency of research reports
Research reports on
Panmure Morning Note 05-02-16
05 Feb 16
The trading update this morning confirms that Shaftesbury's central London villages remain a major tourist attraction for London. The group curates the portfolio well so that streets become destinations with a unique character. The portfolio could not be replicated and positioned with excellent access to transport and the new Crossrail stations, footfall will continue to be amongst the highest in the UK. This will continue to drive demand and push up rents, which remain attractive compared to Regent Street, Oxford Street and Covent Garden. We think that the current weakness provides investors with an excellent opportunity to add to positions. We retain our BUY recommendation and 1106p target price (10% premium to one year forward NAV).
Panmure Morning Note 24-11-15
24 Nov 15
Shaftesbury continually delivers a strong and consistent performance. The group benefits from its Central London focus so that its c600 shops, restaurants and bars enjoy footfall of 40m-50m pa creating a vibrancy which is hard to beat globally and strong demand for its premises. The model is well articulated, established and diligently executed. These results should please the market as they beat consensus for NAV/s, which rose 21.9% to 869p. The outlook remains positive, underpinned by domestic growth in retail sales and high tourist footfall. Shaftesbury is our conviction Buy with a target valuation of 1106p.
Panmure Research - Conviction List Q4 2015 01-10-15
01 Oct 15
9.2% outperformance in Q3 sounds good, but set against a market that fell 9.1% this is hardly a great result. The disparity of performance was enormous with a couple of true mistakes in the Mining and Oil & Gas sector taking a heavy toll. For Q4 we have cut some losses and introduced Greene King, Microfocus and Wentworth on the Long calls with two new high conviction Short calls in Rolls Royce and Majestic Wine. Total outperformance since 2010 is 114% with 2 negative quarters out of 28. It seems there may be some alpha in our analyst's stock knowledge.
Panmure Morning Note 30-09-15
30 Sep 15
Shaftesbury has released a short trading update today highlighting progress with two major schemes and the continued strong trading conditions for its tenants in the core west end of London. We look forward to the results due 11 November 2015 which we anticipate will be strong with an estimated 16.3% rise in NAV/s to 830p. We continue to believe that the shares are undervalued since the estate value does not reflect the unique portfolio which could not be replicated in the heart of London. We retain our BUY recommendation and 1106p target price.
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
Industry fundamentals remain positive
21 Feb 17
The Biotech Growth Trust (BIOG) is a specialist vehicle, aiming to generate long-term capital growth via investment in global biotech stocks. Following a particularly volatile period for the biotech industry, where concerns about drug pricing and investor risk aversion have weighed heavily on stock prices, the managers are hopeful that greater clarity regarding US healthcare policy will lead to continued improved performance of biotech stocks. Industry fundamentals remain attractive, including continued innovation and valuations are very supportive, which offers the potential for higher industry merger and acquisition activity.
Middle Britain growth
21 Feb 17
The Company has achieved our 2017 estimate in 2016 with EBITDA of £2.2m, up 37% on 2015. We upgrade our estimates by 10% at the EBITDA level in 2017. If the shares traded even at the lower end of comparators, they would trade at 17p. We expect the share price to reach our upgraded 17p price target in the short term. Few companies enjoy the unique positioning which Lighthouse has to benefit from the assets of Middle Britain.
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume
Marked confidence in profitability resilience
22 Feb 17
LBG posted a good set of results at the operating level. Management showed its confidence in the group’s ability to protect its indecent profitability levels over the next three years by recommending an increased ordinary dividend and the payment of a special dividend, and by setting a stable return on required equity objectives.
Lloyds, Best Of The Banks
23 Feb 17
Lloyds Banking Group PLC (LLOY) reported a strong result for FY-16, which has allowed it to pay a special dividend, plus has encouraged the UK government to reduce its stake in the bank to below 5%. Lloyds’ acquisition of the MBNA credit card business is proceeding on track, with all key M&A metrics being well satisfied. The outlook for Lloyds’ capital base, its profitability and thus the dividend prospects have all improved. This encourages us to ascribe a Buy rating to the stock, with a target price of 80p per share, derived from a prospective Price / Book value of 1.3x and a P/E ratio of 13x which we think are justifiable ratios.